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Abstract: Ponatinib is a multi-target protein tyrosine kinase inhibitor, and its effects on hepatocellular
carcinoma cells have not been previously explored. In the present study, we investigated its effects
on hepatocellular carcinoma cell growth and the underlying mechanisms. Toward SK-Hep-1 and
SNU-423 cells, ponatinib induces apoptosis by upregulation of cleaved caspase-3 and -7 and promotes
cell cycle arrest in the G1 phase by inhibiting CDK4/6/CyclinD1 complex and phosphorylation
of retinoblastoma protein. It inhibits the growth-stimulating mitogen-activated protein (MAP)
kinase pathway, the phosphorylation of Src on both negative and positive regulation sites, and
Jak2 and Stat3 phosphorylation. Surprisingly, it also activates the PDK1, the protein kinase B
(Akt), and the mechanistic target of rapamycin (mTOR) signaling pathway. Blocking mTOR
signaling strongly sensitizes cells to inhibition by ponatinib and makes ponatinib a much more
potent inhibitor of hepatocellular carcinoma cell proliferation. These findings demonstrate that
ponatinib exerts both positive and negative effects on hepatocellular cell proliferation, and eliminating
its growth-stimulating effects by drug combination or potentially by chemical medication can
significantly improve its efficacy as an anti-cancer drug.
Keywords: ponatinib; proliferation; apoptosis; liver cancer cells; PDK1/Akt/mTOR signaling
1. Introduction
Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality worldwide [1].
Despite rapid progress in liver transplantation, resection, radiofrequency ablation, and
chemoembolization, only one third of patients with HCC are suitable for these treatments [2]. HCC is
also one of the most chemo-resistant tumors because little survival benefits or tumor responses have
been received with many agents [3]. Three small molecule kinase inhibitors, sorafenib, regorafenib,
and lenvatinib, have been approved as targeted therapy for advanced stages of HCC for their effects in
increasing survival and delaying tumor progression [4–6]. All these drugs work mainly as vascular
endothelial growth factor receptor (VEGFR) inhibitors to block angiogenesis. However, their use was
restricted due to the drug resistance and intolerance. Furthermore, in the past few years, multiple
clinical trials with drugs targeting the fibroblast growth factor receptor (FGFR), the VEGFR, the
platelet-derived growth factor receptor (PDGFR), the epidermal growth factor receptor (EGFR), the
insulin-like growth factor 1 receptor (IGF-1R), the mechanistic target of rapamycin (mTOR), and the
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transforming growth beta (TGFβ) signaling pathways have been conducted, but none have been
shown to be effective in improving patient survival [7]. The molecular pathogenic mechanism of
HCC is very complicated, involving up-regulation of Ras/Raf/Mek/Erk and phosphatidylinositol
3-kinase (PI3K)/Akt/mTOR signaling transduction pathways and aberrant expression of receptor
tyrosine kinases [4]. For any signaling inhibitor to be developed into an anticancer drug, it is critical
to understand its molecular mechanisms of action and its effects on oncogenic processes and normal
physiological processes.
Several cell signaling pathways are involved in sustaining cancer cell proliferation, and identifying
specific pathways for a given cancer enables us to design targeted treatments [8]. The mitogen-activated
protein kinase (MAPK) pathway and the pPI3K/Akt/mTOR pathway have emerged as crucial
signaling cascades involved in regulating cell growth, proliferation, and cell death in various cancers [9].
Protein kinase B (Akt) is essentially an anti-apoptotic protein, which phosphorylates various protein
targets controlling cell proliferation, survival and motility [6]. In addition, dysregulated Stat3
signaling is also involved in tumorigenesis by affecting cell growth, angiogenesis and prevention of
apoptosis [10,11].
Receptor and cytosolic protein tyrosine kinases (PTKs) also play crucial roles in driving
proliferation of various cancers. Several rPTKs are critical to HCC development, progression and
metastasis, including EGFR, VEGFR, FGFR, PDGFR, and c-mesenchymal-epithelial transition factor-1
(c-Met) [12–14]. Aberrant Src activity triggers dysregulation of numerous cellular processes including
proliferation, apoptosis, invasion, migration, and angiogenesis, suggesting Src and Src family kinases
play central roles in tumor progression and metastasis [15]. The association between HCC and Src
expression and activation is well established, and activated c-Src may be responsible for malignant
transformation of hepatocytes [16].
Ponatinib (AP24534), an orally available and potent multi-targeted kinase inhibitor, has been
approved by the Food and Drug Administration (FDA) to treat imatinib-resistant patients with chronic
myelogenous leukemia [17,18]. Ponatinib inhibits both native and mutant forms of BCR-ABL, including
the T315I gatekeeper mutant that is resistant to other tyrosine-kinase inhibitors (TKIs) [19,20]. Besides
its activity against BCR-ABL, ponatinib also inhibits approximately 50 other PTKs with IC50 values
below 100 nM, including many kinases in the PDGFR, Src, VEGFR, Eph receptor (EphR), and FGFR
families [20,21]. In a panel of 14 cell lines, including breast, lung, and colon cancer cell lines, ponatinib
inhibited FGFR-mediated signaling and cell growth significantly in a variety of cell lines [22]. Ponatinib
also inhibited the migration and the invasion of breast and orthotopic neuroblastoma cancer cells
in vitro and in mouse models, and the migration and mammosphere formation of breast cancer cells
in vitro and arrested breast cancer lung metastasis in mouse models [23,24].
To date, the effects of ponatinib on HCC have not been determined. In the present study, we
examined the effects of ponatinib on the proliferation, cell cycle, and apoptosis of HCC cells, and
determined its effects on the cell signaling network. This study sheds light on the complicated
molecular mechanisms by which a multi-targeted TKI such as ponatinib can affect the biochemistry
and physiology of targeted cells and reveals approaches that can improve its efficacy. The information
provides a basis for further laboratory research and development of ponatinib as an anti-cancer drug.
2. Results
2.1. Ponatinib Potently Inhibits Viability and Proliferation of HCC Cell Lines
The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was
performed on SK-Hep-1 and SNU-423 cells treated with increasing concentrations of the nine TKIs
(Table 1) for 72 h, and the dose response curves are shown in Figure 1A, and the IC50 values are listed
in Table 2. The most potent inhibitor was ponatinib, which inhibited the viability of the two cell lines
with IC50 of 0.288 ± 0.044 µM (SK-Hep-1) and 0.553 ± 0.041 µM (SNU-423), respectively. Ponatinib
treatment resulted in decreased cell numbers and irregular morphology (Figure 1B) and inhibited
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colony formation of SK-Hep-1 and SNU-423 cells at sub-µM concentrations (Figure 1C). Collectively,
these results indicate that ponatinib potently inhibits the viability and proliferation of these HCC
cell lines.
Table 1. Classification and function of nine protein tyrosine kinase (PTK) inhibitors used in this study.
Drugs MolecularWeight (g/mol) Target PTKs
Ponatinib 532.56
BCR-ABL, VEGFR, PDGFR, FGFR, EpH kinase,
SRC-family protein-tyrosine kinases, and Kit, RET, TIE2,
Flt-3 kinase inhibitor
Sunitinib 398.47 PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, c-KIT,Flt-3, CSF-1R, RET tyrosine kinase inhibitor
Sorafenib 464.83
KIT, Flt-3, VEGFR-2, VEGFR-3, PDGFR-β tyrosine kinase,
C-Raf, B-Raf and mutant B-Raf kinase inhibitor. Unique in
targeting the Raf/Mek/Erk pathway.
Dasatinib 488.01 SRC family (SRC, LCK, YES, FYN) tyrosine kinase,BCR-ABL, c-Kit, EpHA2, PDGFRβ kinase inhibitor
Pazopanib 437.52 VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ, c-kittyrosine kinase inhibitor
Bosutinib 530.45 Src-family (Src, Lyn, Hck) tyrosine kinases, BCR-ABLkinase inhibitor
Gefitinib 446.90 EGFR/Her1/ErbB-1 tyrosine kinase inhibitor
Afatinib 485.94 EGFR (ErbB1)/HER2 (ErbB2)/ HER4 (ErbB4) tyrosinekinase inhibitor
Midostaurin 570.64 PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, Flt-3,PDFRβ and VEGFR1/2 tyrosine kinase inhibitor
The following criteria were used to select drugs for the study: (1) inhibitors that strongly inhibit some cells but not
too many; (2) inhibitors that inhibit a significant number of cells at higher concentration, but the spectrum of cells
are not too broad. An automatic screen was set up based on these two criteria. If an inhibitor inhibited more than
one cell line but fewer than 20 cell lines with IC50 below 0.01 nM, the inhibitor scored one point. If a drug inhibited
between two and 20 cell lines with IC50 below 0.1 nM, it scored one point. With the six-point screen, the scores were
tallied. If a drug scored four or above, the inhibitor was automatically chosen. With these considerations, the nine
PTK inhibitors in the table were chosen. The targeted PTKs of these inhibitors can be found in the two websites
(http://www.drugbank.ca and http://www.rxlist.com).
Table 2. The IC50 (µmol/L) of different single agents in HCC cell lines.
SK-Hep-1 SNU-423
Ponatinib (µmol/L) 0.288 ± 0.044 0.553 ± 0.041
Sunitinib (µmol/L) 0.568 ± 0.070 2.720 ± 0.036
Sorafenib (µmol/L) 3.896 ± 0.037 3.125 ± 0.034
Dasatinib (µmol/L) 0.902 ± 0.107 9.758 ± 0.044
Pazopanib(µmol/L) 3.951 ± 0.041 9.777 ± 0.030
Bosutinib (µmol/L) 0.840 ± 0.042 3.062 ± 0.041
Gefitinib (µmol/L) 5.557 ± 0.029 5.752 ± 0.048
Afatinib (µmol/L) 1.218 ± 0.031 2.400 ± 0.024
Midostaurin (µmol/L) 3.363 ± 0.053 1.640 ± 0.070
The IC50 values were determined from the data in Figure 1A. Individual IC50 results are the mean ± SD from at
least three separate experiments.
Molecules 2019, 24, 1363 4 of 19
Molecules 2019, 24, x FOR PEER REVIEW 4 of 19 
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lines and cytotoxicity of ponatinib. (A) Cell proliferation was examined by 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. HCC cell lines 
including SK-Hep-1 and SNU-423 cells were seeded in 96-well plates and then treated with different 
concentrations of drugs for 72 h. The relative cell viability was calculated and shown. (B) Cell 
proliferation inhibition was observed by microscopy (×100). SK-Hep-1 and SNU-423 cells were 
plated in 24-well plates and exposed to indicated doses of ponatinib for 36 h. (C) SK-Hep-1 and 
SNU-423 cells were plated in six-well plates (500 cells/well) and treated with various concentrations 
of ponatinib for 10 days, then the clonogenic ability was measured and shown. The bars indicate the 
colony formation ability of different groups. Each experiment was carried out three times. (n = 3; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001). 
Table 2. The IC50 (μmol/l) of different single agents in HCC cell lines. 
Figure 1. Efficacy of individual PTK inhibitors against different hepatocellular carcinoma (HCC) cell
lines and cytotoxicity of ponatinib. (A) Cell proliferation was examined by 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. HCC cell lines including SK-Hep-1 and SNU-423
cells were seeded in 96-well plates and then treated with different concentrations of drugs for 72 h.
The relative cell viability was calculated and shown. (B) Cell proliferation inhibition was observed
by microscopy (×100). SK-Hep-1 and SNU-423 cells were plated in 24-well plates and exposed to
indicated doses of ponatinib for 36 h. (C) SK-Hep-1 and SNU-423 cells were plated in six-well plates
(500 cells/well) and treated with various concentrations of ponatinib for 10 days, then the clonogenic
ability was measured and shown. The bars indicate the colony formation ability of different groups.
Each experiment was carried out three times. (n = 3; *, p < 0.05; **, p < 0.01; ***, p < 0.001).
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2.2. Ponatinib Induces Apoptosis in HCC Cells
We determined whether the decrease in cell viability could be attributed to the induction of
apoptosis. SK-Hep-1 and SNU-423 cells were treated with ponatinib for 36 h and stained with Hoechst
33342. As shown in Figure 2A, ponatinib induced apoptosis in the two cell lines in a dose-dependent
manner. Nuclear condensation with bright-blue fluorescence and cellular fragmentation were observed
even at 0.1 µM ponatinib.Molecules 2019, 24, x FOR PEER REVIEW 6 of 19 
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β-Tubulin (co trol) in treated cells.
Molecules 2019, 24, 1363 6 of 19
Cell apoptosis was measured by flow cytometry using the Annecin V-FITC/PI apoptosis detection
kit. After treatment with ponatinib for 36 h, the combined early (lower right quadrant) and late (upper
right quadrant) apoptosis rates in Figure 2B increased with increasing ponatinib concentration. The
apoptosis rate of SK-Hep-1 cells increased from 2.0 ± 0.7% (control) to 7.0 ± 0.92%, 33.1 ± 0.75%,
and 68.9 ± 2.8% when incubated with 0.1, 0.5, and 1 µM ponatinib, respectively. Similarly, that of
SNU-423 cells increased from 6.5 ± 1.44% (control) to 7.8 ± 6.88%, 23.5 ± 1.99%, and 31.9 ± 2.92% by
the same treatments.
Previous reports have demonstrated that ponatinib induces apoptosis in tumor cells through
a caspase 3- and 7-dependent mechanism [22,25–27]. As shown in Figure 2C, ponatinib treatment
promoted cleavage of caspase-3 and -7 in SK-Hep-1 and SNU-423 cells even at 0.1 µM and more
prominently at 1 µM. It was reported previously that caspase-3 and -7 are not only involved in the
execution phase of apoptosis but also regulate events in apoptosis initiation, such as Bax translocation
and cytochrome c release [28,29]. As shown in Figure 2C, ponatinib treatment of SK-Hep-1 and
SNU-423 cells downregulated Bcl-2 and upregulated Bax in a concentration-dependent manner,
indicating that ponatinib-induced apoptosis is associated with the mitochondrial apoptotic pathway.
2.3. Ponatinib Causes Cell Cycle G1 Phase Arrest in HCC Cells
To investigate how the cell cycle is affected, ponatinib-treated SK-Hep-1 and SNU-423 cells
were analyzed by flow cytometry (Figure 3A). The population of cells in the G1 phase increased
with increasing concentrations of ponatinib for both cell lines, suggesting that the drug blocked the
progression from G1 to S phase. Western blotting analysis (Figure 3B) indicated that the drug at 1 µM
resulted in decreased levels of Rb, pRb, CDK4, CDK6, and Cyclin D1, while CDK2 and Cyclin E1 levels
were not affected. Because both CDK4/6/Cyclin D1 and CDK2/Cyclin E1 complexes are capable of
phosphorylating Rb and regulating G1 to S transition, these results suggest that ponatinib blocks G1 to
S transition by reducing CDK4/6/Cyclin D1 function.
Some PTK inhibitors such as gefitinib and crizotinib can cause DNA damage [30,31] and result
in increased expression of RAD51, a DNA repair protein in the homologous recombination repair
pathway [32,33]. We evaluated the expression level of RAD51 in response to ponatinib treatment
(Figure 3C). The RAD51 expression level decreased significantly with ponatinib treatment above
0.5 µM in both SK-Hep-1 and SNU-423, suggesting that the homologous recombination pathway was
activated. Whether this effect was because ponatinib interfered with the homologous recombination
repair signaling or actually resulted in DNA damage was not clear.
2.4. Ponatinib Interferes with Multiple Cell Signaling Pathways in the HCC Cells
The above results demonstrated that ponatinib inhibited cell proliferation, induced apoptosis,
caused cell cycle arrest at G1 phase, and caused DNA damage or interfered with the DNA
damage repair response. We next investigated the activation status of some key PTK-mediated
signaling pathways.
The soluble PTK Src is a well-established oncoprotein contributing to the proliferation of many
types of cancer cells. Ponatinb inhibits Src with an IC50 of 5.4 nM [17]. As shown in Figure 4A,
ponatinib caused an increase in Src expression and a decrease in Src phosphorylation on both Tyr416
and Tyr527 residues in a dose-dependent manner in SK-Hep-1 and SNU-423 cells. Because Src was
activated by autophosphorylation on Tyr416, decreased phosphorylation on Tyr416 indicated that Src
kinase activity was inhibited by ponatinib. Src was inactivated by the phosphorylation on Tyr527,
which was catalyzed by the C-terminal Src kinase (Csk) [34]. The decreased phosphorylation on Tyr527
indicated that Csk was also inhibited by ponatinib. Indeed, ponatinib inhibited Csk with an IC50 of
12.7 nM [17]. The net effect of ponatinib on Src kinase activity was likely a potent inhibition, because
even Src that was unphosphorylated on Tyr527 would still have been inhibited by ponatinib. Because
Src kinase is a key mediator of cell proliferation, inhibition of Src was likely one reason ponatinib
inhibited the proliferation of these cells.
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The MAPK pathway is activated by numerous extracellular signals and regulates cell proliferation,
differentiation, and death. The MAP kinases include ERKs/MEKs, JNKs, and p38/SAPKs families [35],
and ERKs/MEKs are involved in growth regulation. Because ERKs/MEKs are activated by rPTKs,
if ponatinib inhibits any rPTKs, it would cause a down regulation of ERKs and MEKs. As shown
in Figure 4B, Erk1/2 and MEK1/2 expression level did not change, but their phosphorylation levels
decreased by ponatinib treatment, indicating that the MAPK pathway was inactivated by ponatinib.
This was likely due to ponatinib inhibiting upstream rPTKs. More than 25 rPTKs in the EPH, FGFR,
PDGFR, RET, TRK, and VEGFR families were sensitive to ponatinib with IC50 values below 50
nM [17,18]. In contrast, the expression and phosphorylation levels of JNK, c-Jun, and p38 MAPK
were not affected by ponatinib (Figure 4C,D). These results indicated that the growth-stimulating
ERK/MEK MAPK pathway was selectively down regulated by ponatinib, while the JNK/c-Jun and
the p38 MAP kinase pathways, most commonly involved in mediating stress and cytokine responses,
were not affected.
Inhibition of Bcr-Abl was reported to result in downregulation of STAT3 via JAK and MEK
pathways [36], and ponatinib has been reported to inhibit phosphorylation of JAK2 both in BaF3/T315I
cells in vitro and in leukemia models in vivo [37]. Therefore, we analyzed if the JAK2/STAT3 pathway
was affected by ponatinib (Figure 4E). Ponatinib did not affect the expression levels of JAK2 and
STAT3, nor did it affect the phosphorylation levels of p-JAK2 or p-STAT3 in SK-Hep-1 cells. In
SNU-423 cells, however, ponatinib potently inhibited the activation of the JAK2 (p-JAK2) and the
phosphorylation of STAT3 (p-STAT3) without affecting their protein levels. The effect of ponatinib on
JAK2/STAT3 phosphorylation became clear even at 0.1 µM. The cell specificity of SK-Hep-1 versus
SNU-423 indicated that the ponatinib effect on JAK2/STAT3 pathway was cell background-dependent.
2.5. Ponatinib Activates the Akt/mTOR Pathway, and Blocking Akt/mTOR Signaling Sensitizes HCC Cells to
Ponatinib Inhibition
We next investigated the activation status of some key PTK mediated signaling pathways. The
activation of the PI3K/Akt/mTOR signaling pathway is a crucial event in the progression of human
liver cancer [38]. Many PTK inhibitors block cancer cell proliferation by inhibiting the Akt/mTOR
signaling pathway [39–41]. We determined if ponatinib inhibited the HCC cell proliferation by
blocking this pathway (Figure 5A). Both PI3K and p-PI3K levels were low but consistently detectable
in both SK-Hep-1 and SNU-423 cells. PDK1 and Akt protein levels did not change upon ponatinib
treatment, but p-PDK1, p-Akt (S473), and p-Akt (T308) levels increased by ponatinib treatment. The
phosphorylation of both Ser473 and Thr308 was responsible for fully activating Akt [40]. These results
indicated that ponatinib activated PDK1 and Akt in these cells. Activated Akt phosphorylated mTOR
on Ser2448 to positively regulate protein translation [42]. The p-mTOR (S2448) level also increased
with ponatinib treatment (Figure 5A). These results suggested that ponatinib treatment activated the
Akt-mTOR pathway. Time course experiments showed that activation of Akt was time-dependent in
the 36 h treatment period (Figure 5B). These observations were consistent with the observations in
pancreatic ductal adenocarcinoma cells, where ponatinib also increased activation of Akt [41].
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Because ponatinib activates the Akt/mTOR pathway, and the activation of this pathway is
expected to give the cells a survival advantage, we wondered if activation of the Akt/mTOR pathway
compromised ponatinib as a drug against the HCC cells. To test this possibility, we determined if
inhibition of mTOR signaling with mTOR inhibitors rapamycin or temsirolimus would synergistically
enhance the potency of ponatinib (Figure 5C,D). SK-Hep-1 had IC50 values of 0.288 ± 0.044 µM, 0.341
± 0.197 µM, and 1.718 ± 0.282 µM for ponatinib, temsirolimus, and rapamycin, respectively (Figure 5C,
Table 3), while the IC50 values were 0.002 ± 0.001 and 0.019 ± 0.009 µM for the ponatinib+temsirolimus
combination (1:1 ratio) and ponatinib+rapamycin combination (1:1 ratio) (Table 3). Similarly, SNU-423
had IC50 values of 0.553 ± 0.041 µM, 11.407 ± 0.104 µM, and 22.665 ± 0.097 µM for ponatinib,
temsirolimus, and rapamycin, respectively, but the IC50 values were 0.066 ± 0.009 and 0.042 ± 0.007 µM
for the ponatinib+temsirolimus combination and ponatinib + rapamycin combinations, respectively
(Table 3). The combination indexes (CI) at 50% inhibition for both cells were 0.122 or below, indicating
strong synergy between ponatinib and the mTOR inhibitors. This result indicated that the combinations
of ponatinib and mTOR inhibitors were eight to 77 times more potent than their separate effects. The
strong synergy between ponatinib and temsirolimus or rapamycin indicated that blocking the mTOR
signaling pathway made ponatinib much more potent as an inhibitor of proliferation in these two
cells. Blocking Akt activity with MK-2206 had a similar, although less dramatic, synergistic effect on
ponatinib inhibition of SK-Hep-1 and SNU-423 proliferation (Figure 5E,F).
Table 3. Dose-response profiles of ponatinib + temsirolimus and ponatinib + rapamycin drug combinations.
Parameter SK-Hep-1 SNU-423
IC50-ponatinib (µM) 0.288 ± 0.044 0.553 ± 0.041
IC50-temsirolimus (µM) 0.341 ± 0.197 11.407 ± 0.104
IC50-rapamycin (µM) 1.718 ± 0.282 22.665 ± 0.097
IC50-ponatinib + temsirolimus (µM) 0.002 ± 0.001 0.066 ± 0.009
IC50-ponatinib + rapamycin (µM) 0.019 ± 0.009 0.042 ± 0.007
CI50-ponatinib + temsirolimus 0.013 0.122
CI50-ponatinib + rapamycin 0.077 0.078
In treatments, two drugs were used and mixed in a 1:1 molar ratio. The cell proliferation assay was performed using
a serial dilution within the indicated concentration range.
2.6. Ponatinib Did Not Affect PTEN Expression Level
There is an established signaling mechanism that can potentially explain how ponatinib can
activate PDK1 and Akt. PDK1 and Akt are activated by phosphatidylinositol 3,4,5-trisphosphate
(PIP3), and the accumulation of PIP3 is controlled by the balance between phosphatidylinositol
3-kinase and the PTEN phosphatidylinositol 3-phosphatase. Because PI 3-kinase is not affected by
ponatinib, PTEN becomes a plausible candidate for the ponatinib effect. It is established that the PTK
Rak/Frk phosphorylates PTEN on Tyr336 and prevents PTEN degradation by the ubiquitin-mediated
degradation of PTEN [43]. It is also known that ponatinib inhibits Rak/Frk with an IC50 of 1.3 nM. Thus,
it is logical that ponatinib would inhibit Rak/Frk activity, which results in PTEN hypophosphorylation
on Tyr336 and PTEN degradation. The loss of PTEN would lead to the accumulation of PIP3, which
activates PDK1 and Akt. Therefore, we analyzed if PTEN level was affected by ponatinib (Figure 6A,B).
Ponatinib treatment did not have any effect on the expression level of PTEN and might have inhibited
the phosphorylation of PTEN on Ser/Thr residues in SK-Hep-1 and SNU-423 cells. Time course
experiments showed that PTEN level did not change in the 36 h treatment period (Figure 6B). Taken
together, our results suggested that ponatinib did not cause PTEN degradation. It was not clear how
ponatinib activated PDK1 and Akt.
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3. Discussion
Sorafenib, a multiple target tyrosine kinase inhibitor like ponatinib that targets PDGFR, VEGFR,
and Raf kinases, is also one of the FDA-approved targeted therapies for advanced HCC for its
antiproliferative and antiangiogenic effects [4]. However, drug intolerance and resistance to sorafenib
restricted its use after several negative phase III clinical trials. Thus, it is imperative to develop more
powerful kinase inhibitors that can effectively block HCC proliferation.
The original objective of this work was to determine what signaling drugs the HCC cell lines
would be sensitive to and then use that information to elucidate the signaling mechanisms that drive
the proliferation of these cells and to develop a strategy to treat such cancer cells. The initial screening
revealed that ponatinib was the most potent inhibitor for the HCC cell lines. Characterization of the
HCC cell response to ponatinib revealed that ponatinib had a complex and wide spread effect on the
HCC cells. Some of the effects were consistent with the objective of blocking HCC cell proliferation, and
others may have been counterproductive toward that objective. Elucidating the complex interactions
between a drug and the complex signaling network of the target cells is essential in understanding the
efficacy or the ineffectiveness of a drug and provides a basis for designing a more effective drug.
The overall objective of the current study was to understand the complicated effects of ponatinib
on HCC cell lines SK-Hep-1 and SNU-423, which might be the foundation for developing an effective
treatment. With this purpose, we first explored the response of two HCC cell lines to nine tyrosine
kinase inhibitors and found ponatinib displayed the best inhibition. Then, we investigated the effects
of ponatinib on the proliferation of SK-Hep-1 and SNU-423 cells. Our results showed that ponatinib
caused apoptosis in SK-Hep-1 and SNU-423 cells, which was confirmed by the upregulation of
caspase-3/7 activity. The cells accumulated in the G1 phase in response to the treatment, which was
apparently caused by inhibiting the CDK4/6/Cyclin D1 complex. Moreover, the inhibition of the cell
cycle progression seemed to be due to the inhibition of the ERK pathway, as Mek 1/2 and Erk 1/2
phosphorylation level all decreased. We also observed activation of the Akt/mTOR pathway in both
cells and inhibition of Jak2/Stat3 only in SNU-423 cells.
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Many potent inhibitors have been developed against well-established oncogenic kinases, yet such
inhibitors often fail in clinical trials as effective drugs. The reasons are likely multiple and complex,
and understanding the reasons behind the failures holds the key to developing more effective targeted
therapy. The findings in the current study provide an example for one such reason. Ponatinib is
a potent multi-targeted PTK inhibitor and is a very useful and critical agent for chronic myeloid
leukemia (CML) and philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL),
particularly those with T315I mutations. In addition to inducing apoptosis and inhibiting cell division
and proliferation by blocking several proliferation-stimulating signaling pathways, it also activates the
PDK1/Akt/mTOR survival pathway, which severely compromises ponatinib as an anti-cancer drug.
Ponatinib inhibits nearly half (28 receptor PTKs and 15 soluble PTKs) of all human PTKs (total
= 94) with IC50 values below 50 nM [17]. Consistent with this broad specificity, ponatinib causes
apoptosis and induces cell cycle arrest at the G1 phase in SK-Hep-1 and SNU-423 HCC cells. At the
molecular level, apoptotic caspase-3/7 activities are activated, and the CDK4/6/Cyclin D1 complex is
inhibited by ponatinib. A number of kinase signaling pathways are inhibited by ponatinib, including
the MAPK pathway, the Src signaling pathway, and the JAK2/STAT3 pathway. Inhibition of these
pathways is likely contributing to the anti-proliferative effects of ponatinib.
Surprisingly, ponatinib also activates the PDK1/Akt/mTOR signaling pathway. This activation
reduces the effectiveness of ponatinib as an inhibitor against HCC proliferation. Even though the
mTOR and Akt inhibitors alone are not potent inhibitors of HCC cell proliferation, they dramatically
sensitize the cells to killing by ponatinib, indicating that the activation of PDK1/Akt/mTOR likely
enhances the ability of the cells to survive. This result suggests that ponatinib would have been a
much more potent inhibitor for HCC cells had it not activated the PDK1/Akt/mTOR pathway. There
are conflicting reports on if ponatinib inhibits [20,44,45] or activates [41] Akt signaling in the literature.
The discrepancy suggests that the effects of ponatinib on Akt signaling may be dependent on cell
signaling background.
The findings suggest that the unintended activation of the PDK1/Akt/mTOR may be one reason
why a potent PTKI such as ponatinb, despite its potent inhibition of its intended targets, may not work
well against some cancers. The results suggest two potential approaches to overcome this problem. In
the long term, developing PTK inhibitors that only inhibit the cancer promoting pathways without
activating Akt would offer the best hope for effective agents for targeted therapy. For this purpose,
elucidating the molecular mechanisms of drug action is essential. In the short term, combination of
Akt/mTOR pathway inhibitors with ponatinib can also overcome this obstacle.
In addition to ponatinib, other PTK inhibitors have been reported to activate Akt. Another broad
PTKI, dasatinib, has also been shown to activate Akt [46]. Crizotinib, a Met kinase inhibitor, was shown
to activate Akt signaling in gastric cancer cells [31], even though it had an overall antiproliferative
effect on these cells. Furthermore, co-inhibition of Akt signaling enhanced the anti-proliferative
effect of crizotinib on gastric cancer cells, indicating that the activation of the Akt pathway was
counterproductive in crizotinib’s antiproliferative effect on gastric cancer cells. U0126, a non-ATP
competitive MEK inhibitor, was also shown to trigger significant increase in Akt phosphorylation
at both S473 and T308 in neural progenitor cells [47]. Thus, activation of Akt/mTOR signaling may
be an undesirable side effect for many PTK inhibitors. How wide spread this phenomenon is awaits
further investigation.
The effects of ponatinb on HCC cell signaling are complex but consistent with published data.
The inhibition of phosphorylation of Src on Tyr527 is likely due to ponatinib inhibiting Csk (IC50 =
12.7 nM) [17]. Even though blocking Tyr527 phosphorylation on Src is supposed to activate Src activity,
this activation is likely inconsequential in its overall effect on Src function, because Src activity is also
inhibited by ponatinib. Ponatinib also inhibits Jak2 with an IC50 less than 200 nM [17].
A broad spectrum PTK inhibitor can be beneficial if multiple PTKs are contributing to a cancer
cell’s proliferation, and a multi-PTK inhibitor such as ponatinib can be used to block all the involved
PTKs. However, a broad spectrum PTK inhibitor may block other PTKs that may play important
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normal physiological functions. Inhibiting such PTKs may result in undesirable effects such as
activating Akt/mTOR pro-survival signaling or even cellular toxicity. Although we focused on a few
cancer-relevant signaling pathways, the effect of ponatinib on other PTKs may also have important
impacts on cell physiology, including potential cytotoxic effects. Indeed, there are numerous reports
of toxicity caused by ponatinib and other broad spectrum PTK inhibitors. For example, treatment of
HepG2 liver cancer cells with ponatinib at low µM concentrations resulted in severe mitochondrial
toxicity and diminished ATP production [48]. All approved BCR-ABL inhibitors display some levels
of myocyte, cardiovascular and hepatic toxicity, and the toxicity in general correlates to the lack of
specificity [49–51]. In addition, toxicities concerned with TKIs also include hyperglycemia, pulmonary
hypertension, pneumonitis, pleural effusion, musculoskeletal pain, lipase elevation/pancreatitis,
and myelosuppression [52,53]. Careful management of the off-target side effects without losing the
on-target benefit would be a key to effective development and application of such inhibitors.
In conclusion, our present study indicates that ponatinib can induce cytotoxicity,
caspase-dependent cell apoptosis, and cell cycle arrest, which might be a potential agent for liver cancer
treatment. The study provides evidence ponatinib inhibits a number of pathways to lead to tumor
inhibition. In future studies, gene knockout or silencing of particular pathways will be able to provide
further confirmation for such mechanisms. In addition, in vivo studies of ponatinib treatment alone or
in combination with Akt/mTOR inhibitors will also provide further validation of the conclusion.
4. Materials and Methods
4.1. Cell Lines and Cell Culture
Human HCC cell line SK-Hep-1 was purchased from Cell Bank of Chinese Academy of Sciences
(Shanghai, China) in October 2016. Human HCC cell line SNU-423 was purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) in October 2016. They were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Hyclone, Logan, UT, USA) (SK-Hep-1) or Roswell Park Memorial
Institute 1640 Medium (RPMI-1640) (Hyclone, Logan, UT, USA) (SNU-423) supplemented with 10%
fetal bovine serum. All cells were incubated in a humiliated atmosphere with 5% CO2 at 37 ◦C.
The culture medium was changed two to three times a week. The two cell lines were tested and
authenticated using short tandem repeat (STR) matching analysis. The Cell Bank of Chinese Academy
of Sciences (Shanghai, China) routinely performs single nucleotide polymorphism (SNP) and STR
analysis to confirm cell line identity.
4.2. Materials and Antibodies
All inhibitors were purchased from Selleck Chemicals (Houston, TX), prepared as 10 mM stock
solutions in DMSO, and further diluted with culture medium before use. Annexin V-FITC/PI apoptosis
detection kit and cell cycle detection kit were purchased from KeyGen BioTECH (Nanjing, China).
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMSO, and Hoechst 33342
were obtained from Solarbio (Beijing, China). Antibodies for Src/p-Src, Mek/p-Mek, Erk/p-Erk,
PI3K/p-PI3K, PDK1/p-PDK1, AKT/p-AKT, mTOR/p-mTOR, PTEN/p-PTEN(S380/T382/383),
JNK/p-JNK, c-Jun, p38/p-p38, JAK2/P-JAK2, Stat3/p-Stat3, Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2,
Cyclin E1, RAD51, Bcl-2, Bax, cleaved caspase-3, and cleaved caspase-7 were all purchased from Cell
Signaling Technology (Danvers, MA, USA). Tubulin and GAPDH primary antibodies were purchased
from ZSGB-Biotechnology (Beijing, China). Horseradish peroxidase (HRP)-conjugated secondary
antibodies against rabbit and mouse IgG were obtained from BBI life sciences (Shanghai, China).
4.3. Cell Proliferation Assay
Cell viability was determined using the MTT assay. Cells (3–5 × 103 cells/well) were seeded in
96-well flat-bottomed plates and cultured for 24 h. Then, the kinase inhibitors were diluted into the
medium in a 2-fold dilution series (0.0012 to 20 µM) and added into the wells after the medium in the
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well was removed. After 72 h of treatment, 50 µL MTT solution (5 mg/mL) was added to each well
after the medium was removed, and the cells were incubated for 4 h at 37 ◦C. Then, the medium was
removed, and 200 µL DMSO was added to each well. Absorbance at 492 nm was measured using a
BioTek microplate reader (Winooski, VT, USA). Half-maximal inhibitory concentration (IC50) values
were estimated using SPSS 19.0 software. Each experiment was performed in triplicates and at least
three times.
4.4. Colony Formation Assay
SK-Hep-1 and SNU-423 cells (500 cells) were plated in 6-well plates. After 24 h incubation,
the cells were treated with various concentrations of ponatinib and then cultured for an additional
10 days. Then, the cells were stained with 0.5% crystal violet and photographed. The absorbance of
stained cells at 595 nm was measured using a BioTek microplate reader (Winooski, VT, USA). The
clone formation rate was calculated as follows: colony formation (% of control) = (ODtreated cells −
ODblank)/(ODcontrol − ODblank) × 100%.
4.5. In-Vitro Drug Combination Study
To test if treatment with rapamycyn or temsirolimus would sensitize the HCC cells to ponatinib
treatment, cells were treated with ponatinib, rapamycin, and temsirolimus, either alone or in
combination with a series of drug concentrations. MTT assay was used to measure cell proliferation.
To evaluate the interaction between two drugs, the Chou-Talalay method was used to calculate
the combination index [54]. The combination index (CI) = D1/D’1 + D2/D’2, in which D1 and D2
were the concentrations of drug 1 and drug 2 in the combination that achieved a certain percentage of
inhibition, while D’1 and D’2 were concentrations of drug 1 or drug 2 alone to achieve the same level
of inhibition.
4.6. Apoptosis Assay
The Annecin V-FITC/PI apoptosis detection kit was used for the apoptosis assay. For analysis of
cell apoptosis, cells were treated with ponatinib for 36 h, washed twice with phosphate buffered saline
(PBS), digested with 0.25% trypsin without ethylenediaminetetraacetic acid (EDTA), and centrifuged
at 1000 rpm for 3 min. Then, the cells were harvested, and the concentration was adjusted to 1 ×
106 cells/mL. The cells were resuspended in 500 µL binding buffer and dyed with 5 µL Annecin
V-FITC and 5 µL PI for 15 min at 37 ◦C. The apoptosis rate was measured with a BD FACSCanto II
flow cytometer (BD Biosciences, San Jose, CA, USA). Experiments were performed three times for
each group.
4.7. Cell Cycle Analysis
A cell cycle detection kit was used for the cell cycle analysis. Cells were treated with ponatinib for
36 h, collected, and fixed in 70% ethanol at 4 ◦C overnight. Following the manufacturer’s protocol,
cells were washed twice with PBS and treated with RNase A and propidium iodide (PI) at 37 ◦C for
1 h. Then, the samples were measured using a flow cytometer.
4.8. Morphological Analysis by Hoechst Staining
Cells (1 × 105 cells/well) were seeded in a 6-well plate for 24 h before treatment with various
concentrations of ponatinib for 36 h. Then, the cells were washed three times with PBS and stained with
Hoechst 33342 according to the manufacturer’s protocol. Nuclear morphology of cells was examined
under a fluorescence microscopy (Olympus, 1X51, Tokyo, Japan).
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4.9. Western Blot Analysis
After treatment with ponatinib for 36 h, cells were suspended in radio-immunoprecipitation
assay (RIPA) cell lysis buffer and lysed by homogenization. The cell lysates were collected by
centrifugation, and the protein concentration was quantified using the BCA protein quantitation
kit (Boster Biotechnology, Wuhan, China). A total of 100 µg protein per sample was separated by
SDS-PAGE and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica,
MA, USA). The membranes were blocked using 5% skim milk at room temperature for 1 h and
incubated at 4 ◦C overnight with primary antibodies in 5% skim milk. Primary antibodies were
detected with a corresponding HRP-conjugated IgG antibody, and bands were visualized using an
enhanced chemiluminescent (ECL) blot detection system (Transgene, Beijing, China). Image J software
was used to quantify the grey value of the bands.
4.10. Statistical Analysis
Statistical analyses were carried out using the SPSS 19.0 statistical software (SPSS Inc., Chicago,
IL, USA). Statistical significance was analyzed using Student’s t-test, and p < 0.05 was considered
statistically significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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